文献速递类风湿关节炎

接受托珠单抗和传统合成改善病情抗风湿药治疗的类风湿关节炎女性的生殖状态与外源性性激素使用

Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs.
PubMed 文献 · Rheumatology (Oxford) · 2023-01-01

汇总五项3期临床试验的4474例女性类风湿关节炎患者个体数据,分析绝经状态及外源性性激素使用与首次缓解时间的关系。围绝经期患者较绝经前缓解率降低(校正HR 0.78),使用外源性性激素与缓解率升高相关(校正HR 1.20)。

要点

  • 围绝经期类风湿关节炎患者较绝经前患者首次缓解率降低,校正HR 0.78(95% CI 0.61, 0.99)。
  • 使用外源性性激素与女性类风湿关节炎患者首次缓解率升高相关,校正HR 1.20(95% CI 1.01, 1.43)。
  • 外源性性激素与缓解的关联在围绝经期和绝经早期患者中似乎更明显,原文认为需进一步研究确认。

核心结论

  • 围绝经期女性类风湿关节炎患者较绝经前患者更不易达到缓解。
  • 使用外源性性激素似乎与女性类风湿关节炎患者更频繁的缓解相关,尤其在围绝经期和绝经早期患者中,但原文认为需进一步研究确认并识别驱动因素及其与绝经状态的交互作用。

研究设计与样本

  • 汇总五项3期临床试验的个体参与者数据,这些试验中类风湿关节炎患者接受托珠单抗和/或传统合成改善病情抗风湿药治疗。
  • 分析纳入4474例女性患者,主要结局为根据简化疾病活动指数评估的首次缓解时间,采用Cox比例风险分析评估绝经状态或外源性性激素使用与首次缓解时间的关系。
  • 分析变量包括性别、基线绝经状态(绝经前、围绝经期、绝经早期和绝经后)、年龄、体重指数、种族、既往改善病情抗风湿药数量和基线疾病活动度。

主要发现

  • 4474例女性患者中,绝经后2817例(62.9%)、绝经早期202例(4.5%)、绝经前1021例(22.8%)、围绝经期414例(9.2%)。
  • 上述各组中分别有221例(7.8%)、13例(6.4%)、255例(25%)和47例(11.4%)使用外源性性激素。
  • 汇总分析中,围绝经期状态与绝经前状态相比与缓解减少相关,校正HR 0.78(95% CI 0.61, 0.99)。
  • 使用性激素与显著更高的缓解相关,校正HR 1.20(95% CI 1.01, 1.43)。

关键数值与推荐

  • 围绝经期 vs 绝经前:校正HR 0.78(95% CI 0.61, 0.99),围绝经期缓解减少。
  • 使用外源性性激素 vs 未使用:校正HR 1.20(95% CI 1.01, 1.43),使用性激素与缓解升高相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文结论指出需进一步研究以确认并识别该观察的驱动因素及其与绝经状态的交互作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Sex is well known to influence risk, severity and treatment outcomes of RA, although the underlying causes are uncertain. The aim of this research was to examine whether factors influencing female sex hormones (reproductive status and exogenous sex hormone use) are associated with the efficacy of DMARDs. METHODS: Individual participant data were pooled from five phase 3 clinical trials where RA patients were treated with tocilizumab and/or conventional synthetic DMARDs. The primary outcome was the time to first remission according to the Simplified Disease Activity Index. The relationship between menopausal status or use of exogenous sex hormones and the time of first remission was assessed via Cox proportional analysis. Analysed data included sex, baseline menopausal status (premenopausal, perimenopausal, early postmenopausal and postmenopausal), participant age, body mass index, race, number of previous DMARDs and baseline disease activity. RESULTS: Analysis included 4474 female patients, of whom 2817 (62.9%) were postmenopausal, 202 (4.5%) were early postmenopausal, 1021 (22.8%) were premenopausal and 414 (9.2%) were perimenopausal. Of these, 221 (7.8%), 13 (6.4%), 255 (25%) and 47 (11.4%), respectively, were taking exogenous sex hormones. In the pooled analysis, perimenopausal status was associated with reduced remission compared with premenopausal status [adjusted HR 0.78 (95% CI 0.61, 0.99)]. Sex hormone use was associated with significantly higher remission [adjusted HR 1.20 (95% CI 1.01, 1.43)]. CONCLUSION: Perimenopausal women were less likely to achieve remission compared with premenopausal RA patients. The use of exogenous sex hormones appeared to be associated with more frequent remission in female RA patients, particularly those who were perimenopausal and early postmenopausal, although further research is required to confirm and identify the drivers for this observation and how it interacts with menopausal status.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Daraghmeh DN, Hopkins AM, King C, et al. Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs. Rheumatology (Oxford). 2023. PMID: 35731132. doi:10.1093/rheumatology/keac357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。